ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » SLE – Clinical Poster I: Epidemiology & Pathogenesis

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM
Abstract Number: 646
A Meta-Analysis of Anti-Ribosomal P Autoantibodies in Systemic Lupus Erythematosus: A Misunderstood Autoantibody
9:00AM-11:00AM
Abstract Number: 641
A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 705
A Tale of Three Cohorts: SLE Criteria in Developed vs Developing Countries
9:00AM-11:00AM
Abstract Number: 691
Adjusted GAPSS in Systemic Lupus Erythematosus Patients in Argentina
9:00AM-11:00AM
Abstract Number: 674
Affordability Concerns Prevalent Among Patients with Systemic Lupus Erythematosus (SLE)
9:00AM-11:00AM
Abstract Number: 639
African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup
9:00AM-11:00AM
Abstract Number: 660
Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease
9:00AM-11:00AM
Abstract Number: 654
Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease
9:00AM-11:00AM
Abstract Number: 655
Assessing Perceptions, Barriers, and Preferences to Exercise in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 670
Association Between Ambient Air Pollutant Exposures and Childhood-Onset Systemic Lupus Erythematosus: A 12-Year Population-Based Cohort Study in Taiwan
9:00AM-11:00AM
Abstract Number: 643
Association Between Neutrophil to Lymphocyte, Monocyte to Lymphocyte, and Platelet to Lymphocyte Ratios and Lupus Disease Activity and Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 686
Association Between the Soluble Terminal Complement Complex C5b-9 (sC5b-9) and Signs of Active Kidney Disease in a Swiss SLE Cohort
9:00AM-11:00AM
Abstract Number: 645
Association of Co-positivity for Anti-dsDNA, -Nucleosome, and -Histone Antibodies and Disease Activity in Patients with Lupus Nephritis: Results from the KORNET Registry
9:00AM-11:00AM
Abstract Number: 701
Association of Cumulative Urinary Podocyte Number and Urinary Podocalyxin with Long-term Renal Prognosis in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 661
Association of Serum and Urine Levels of TWEAK, MCP-1 and NGAL with Disease Activity in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 683
Biologic Differences Between Type 1 and 2 Lupus
9:00AM-11:00AM
Abstract Number: 694
Body Mass Index at Time of Diagnosis Is Predictive of Future Disease Activity in SLE
9:00AM-11:00AM
Abstract Number: 687
CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race
9:00AM-11:00AM
Abstract Number: 675
Clinical and Serological Lupus Activity Before and After Developing End Stage Renal Disease
9:00AM-11:00AM
Abstract Number: 684
Clinical Biomarkers at Renal Flare Are Associated with Histologic Changes in Repeat Renal Biopsy in Patients with Biopsy-proven Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 673
Clinical Characteristics of Lymphadenopathy in Systemic Lupus Erythematous: A Case Control Study from a Tertiary Care Center
9:00AM-11:00AM
Abstract Number: 652
Clinical Relevance According to Staining Patterns and Titers of Antinuclear Antibody
9:00AM-11:00AM
Abstract Number: 676
Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments
9:00AM-11:00AM
Abstract Number: 688
Comparison of the Physicians’ Clinical Diagnosis and the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Multiethnic Cohort
9:00AM-11:00AM
Abstract Number: 669
Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria
9:00AM-11:00AM
Abstract Number: 642
Complement Deposition C4d on Platelets Is Associated with Vascular Events in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 682
Correlation Between the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) and Health-Related Quality of Life (HRQoL) and Other PROs in a Primarily Mestizo Population
9:00AM-11:00AM
Abstract Number: 692
Correlation of Urinary Soluble CD163 Levels with Clinicopathological Features in Lupus Nephritis: Its Role as a Potential Biomarker
9:00AM-11:00AM
Abstract Number: 644
Decreased HVEM Expression in Lupus Patients and Impact of HVEM Knockout Mouse Model of Lupus Suggest a Role for BTLA Signaling in Disease Pathogenesis
9:00AM-11:00AM
Abstract Number: 697
Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients
9:00AM-11:00AM
Abstract Number: 659
Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity
9:00AM-11:00AM
Abstract Number: 658
Disentangling Connective Tissue Diseases: Overlaps and Disparities in Clinical Diagnosis, Classification Criteria and Autoantibodies – Results from the Lupus Extended Autoimmune Phenotype Study
9:00AM-11:00AM
Abstract Number: 640
Elevated Serum Interleukin-23 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity, Clinical and Immunological Markers
9:00AM-11:00AM
Abstract Number: 695
Environmental and Atmospheric Factors in Systemic Lupus Erythematosus: A Regression Analysis
9:00AM-11:00AM
Abstract Number: 681
Evaluation of the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Clinician Reported Outcome (ClinRO) and Patient Reported Outcome (PRO) in a Primarily Mestizo Population
9:00AM-11:00AM
Abstract Number: 693
Hair Chemicals and Systemic Lupus Erythematosus: A Case-Control Study
9:00AM-11:00AM
Abstract Number: 637
How Often Should SLE Patients Be Tested for Lupus Anticoagulant?
9:00AM-11:00AM
Abstract Number: 704
Improving Patient-Centered Care by Utilizing Lupus Wellness Program
9:00AM-11:00AM
Abstract Number: 647
Is ANA-status at Disease Inception Associated with Long-term Damage Accrual and Direct and Indirect Health Care Costs in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort?
9:00AM-11:00AM
Abstract Number: 668
Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with Systemic Lupus Erythematosus (SLE) in the Detroit, MI Area, a High Risk Population
9:00AM-11:00AM
Abstract Number: 679
Longitudinal Changes in Manifestations of SLE
9:00AM-11:00AM
Abstract Number: 638
Longitudinal Trends for Estimated Glomerular Filtration Rate and Predictors of Change in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 698
Measurement of Type I IFNα Production at the mRNA Level and Its Potential Use as a Biomarker in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 672
Mouse SLE Studies Do Not Describe Human SLE
9:00AM-11:00AM
Abstract Number: 664
Myxovirus Resistance Protein a Is a Useful Additional Histological Marker for Cutaneous Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 685
Neutrophil Lymphocyte Ratio as a Marker for Immune Complex-Driven Inflammation in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 653
Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 648
Patients of African Descent Score Higher on Quality of Life Indices Despite Their Known Disease Severity
9:00AM-11:00AM
Abstract Number: 680
Patients Who Do Not Fulfill the 2018 EULAR/ACR Criteria for Systemic Lupus Erythematosus Accrue Less Damage: Data from a Multicenter, Multiethnic US Cohort
9:00AM-11:00AM
Abstract Number: 689
Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 677
Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery
9:00AM-11:00AM
Abstract Number: 657
Performance of the “Do You Know What I Mean” Questionnaire in the Assessment of Disease Knowledge in Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 678
Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease
9:00AM-11:00AM
Abstract Number: 650
Performance of the Proposed American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Lupus Erythematosus in Korean Patients
9:00AM-11:00AM
Abstract Number: 663
Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 671
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
9:00AM-11:00AM
Abstract Number: 649
Potentially Reversible Associations with Fatigue in SLE Patients – Results from a Single-centre Study
9:00AM-11:00AM
Abstract Number: 651
Predictors of Renal Damage in Systemic Lupus Erythematosus Patients from Latin America
9:00AM-11:00AM
Abstract Number: 703
Prior Knowledge Feature Reduction Improves Performance in a Machine Learning Model of Systemic Lupus Erythematosus Flare Status Using Serum Proteomics
9:00AM-11:00AM
Abstract Number: 699
Revising the SLEDAI-2K to Include Additional Constitutional Symptoms to More Accurately Assess Lupus Disease Activity
9:00AM-11:00AM
Abstract Number: 702
Seasonality of Cutaneous and Systemic Flares in Adults and Children in the Einstein Lupus Cohort
9:00AM-11:00AM
Abstract Number: 666
Sensitivity to Change of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
9:00AM-11:00AM
Abstract Number: 656
Serum Albumin as a Long-term Predictor of Renal Evolution in Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 700
Sleep Quality Among Patients with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 696
The Performance of a Renal Activity Index in Lupus Nephritis in Induction Therapy
9:00AM-11:00AM
Abstract Number: 667
The PROMIS-29 as a Measure of Type 1 and 2 SLE Activity
9:00AM-11:00AM
Abstract Number: 690
Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment
9:00AM-11:00AM
Abstract Number: 662
Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 665
Utility of Repeat Renal Biopsies in Patients with Lupus Nephritis in Western Australia
9:00AM-11:00AM
Abstract Number: 636
Validation and Transcultural Adaptation of the Spanish Version of Brief Index of Lupus Damage (BILD) Questionnaire

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology